Brii Bio Reports 41.9% HBsAg Loss Rate at End of Treatment in Phase 2 ENRICH Trial

• Brii Biosciences presented Phase 2b ENRICH and ENHANCE results at AASLD 2026, supporting BRII-179-based strategies for hepatitis B functional cure.
• ENRICH reproduced earlier findings that BRII-179 priming supported sustained hepatitis B surface antigen loss following combination treatment.
• ENHANCE combination therapy achieved greater antigen clearance than interferon alone, including among participants with higher baseline antigen levels.
• A separate ENHANCE regimen shortened interferon treatment while maintaining comparable antigen clearance, supporting further evaluation of immune priming.
• Regimens were generally well tolerated; no new or unexpected safety signals emerged in ENHANCE’s concurrent combination treatment group.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611051900PR_NEWS_USPR_____CN90020) on November 06, 2026, and is solely responsible for the information contained therein.